GHRELIN ANTAGONISM IN APPETITE AND ADIPOSITY

食欲和肥胖中的生长素释放肽拮抗作用

• 批准号: 8357660
• 负责人: RAUL A BASTARRACHEA
• 金额: $ 2.08万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357660
• 关键词: Anti-Obesity Agents; Brain; Cardiovascular Diseases; Desire for food; Disease; Eating; Effectiveness; Energy Metabolism; Funding; Grant; Hormones; Human; Hypothalamic structure; National Center for Research Resources; Neurons; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Peripheral; Primates; Principal Investigator; Research; Research Infrastructure; Resources; Risk Factors; Source; Testing; United States National Institutes of Health; cancer type; cost; ghrelin; improved; insulin sensitivity

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Obesity represents a major risk factor for diseases such as type 2 diabetes, cardiovascular disease and certain types of cancer. The hypothalamus in the brain is the central regulator of food intake and thus is a key target for anti-obesity drugs. Ghrelin is a peripheral hormone that acts on hypothalamic neurons to increase food intake. Human studies have shown that infusing ghrelin increases food intake and decreases energy expenditure. However, no human studies have been undertaken to test whether a ghrelin antagonist will have the opposite effects i.e. will decrease food intake. This proposal will evaluate the effectiveness of ghrelin antagonist in decreasing appetite and adiposity and improving insulin sensitivity.

该子项目是利用资源的众多研究子项目之一 由 NIH/NCRR 资助的中心拨款提供。子项目的主要支持 并且子项目的首席研究员可能是由其他来源提供的， 包括其他 NIH 来源。 子项目可能列出的总成本 代表子项目使用的中心基础设施的估计数量， NCRR 赠款不直接向子项目或子项目工作人员提供资金。 肥胖是 2 型糖尿病、心血管疾病和某些类型癌症等疾病的主要危险因素。大脑中的下丘脑是食物摄入的中枢调节器，因此是抗肥胖药物的关键靶点。生长素释放肽是一种外周激素，作用于下丘脑神经元以增加食物摄入量。人体研究表明，注射生长素释放肽可以增加食物摄入量并减少能量消耗。 然而，尚未进行人体研究来测试生长素释放肽拮抗剂是否会产生相反的作用，即减少食物摄入量。该提案将评估生长素释放肽拮抗剂在降低食欲和肥胖以及改善胰岛素敏感性方面的有效性。